Preferred Sample Type
Specimen Transport
Standard transport to laboratoryTurnaround Time
7 daysSample Stability
4 hoursEdoxaban Assay
General Information
Edoxaban is one of the direct oral anticoagulants, exerting an anticoagulant effect by inhibiting activated factor X.
Changes in the prothrombin time (PT), international normalized ratio (INR), and activated partial thromboplastin time (aPTT) may be observed in patients on therapeutic edoxaban doses. However, these changes tend to be small, unpredictable, and highly variable, so clinicians should not use these markers to monitor the anticoagulant effects or titrate the dose of edoxaban (Plitt A, Giugliano RP. Edoxaban: review of Pharmacology and key phase I to III clinical trials. J Cardiovasc Pharmacol Ther. 2014;19(5):409–416)
Notes:
Urgent requests should be discussed with the laboratory prior to receiving the sample.
Notes
Urgent requests should be discussed with the laboratory prior to receiving the sample
Reference Range
Edoxaban is reported as ng/mL
For patient’s receiving 60mg edoxaban, peak plasma levels have been recorded as appox. 125-245 ng/ml for stroke prevention in NVAF, and appox. 149-317ng/ml for treatment of PE/VTE.1
For patient’s receiving 30mg edoxaban, peak plasma levels have been recorded as 60-120ng/ml2
1. ‘ICSH Recommendations for Laboratory Measurement of Direct Oral Anticoagulants’, Gosselin et.al, Thromb Haemost 2018’
2. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation’ Weitz et al, Thromb Haemost 2010
Specifications
- EQA Scheme?: No